Tracking the Evolution of Resistance to ALK Tyrosine Kinase Inhibitors through Longitudinal Analysis of Circulating Tumor DNA

about

Clinical utility of cell-free DNA for the detection of ALK fusions and genomic mechanisms of ALK inhibitor resistance in non-small cell lung cancer.Lorlatinib in ALK- and ROS1-positive NSCLC: the future has a start.

P2860

Q52723096-0858A410-3C1C-4AAE-913F-396E98FAF626 Q55055819-45C17E71-BC55-4A3A-9B1D-0B81AA677287

P2860

Tracking the Evolution of Resistance to ALK Tyrosine Kinase Inhibitors through Longitudinal Analysis of Circulating Tumor DNA

Item

http://www.wikidata.org/entity/Q56890749

description

scientific article published on 23 January 2018

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована у 2018

@uk

name

Tracking the Evolution of Resi ...... lysis of Circulating Tumor DNA

@en

Tracking the Evolution of Resi ...... lysis of Circulating Tumor DNA

@nl

type

Item

label

Tracking the Evolution of Resi ...... lysis of Circulating Tumor DNA

@en

Tracking the Evolution of Resi ...... lysis of Circulating Tumor DNA

@nl

prefLabel

Tracking the Evolution of Resi ...... lysis of Circulating Tumor DNA

@en

Tracking the Evolution of Resi ...... lysis of Circulating Tumor DNA

@nl

P1476

Tracking the Evolution of Resi ...... lysis of Circulating Tumor DNA

@en

P2093

A John Iafrate

http://www.w3.org/2001/XMLSchema#string

A Rose Brannon

http://www.w3.org/2001/XMLSchema#string

Aaron N Hata

http://www.w3.org/2001/XMLSchema#string

Alice T Shaw

http://www.w3.org/2001/XMLSchema#string

Anna F Farago

http://www.w3.org/2001/XMLSchema#string

Catarina D Campbell

http://www.w3.org/2001/XMLSchema#string

Christopher G Azzoli

http://www.w3.org/2001/XMLSchema#string

Cyril H Benes

http://www.w3.org/2001/XMLSchema#string

Harper Hubbeling

http://www.w3.org/2001/XMLSchema#string

Ibiayi Dagogo-Jack

http://www.w3.org/2001/XMLSchema#string

P2860

Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib

First-line crizotinib versus chemotherapy in ALK-positive lung cancer.

Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial.

Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial.

Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK

Pindel: a pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads

Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA

Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples.

Bias-Corrected Targeted Next-Generation Sequencing for Rapid, Multiplexed Detection of Actionable Alterations in Cell-Free DNA from Advanced Lung Cancer Patients.

Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients.

P31

scholarly article

P356

10.1200/PO.17.00160

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

2018

http://www.w3.org/2001/XMLSchema#string

P50

Satoshi Yoda

P577

2018-01-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29376144

http://www.w3.org/2001/XMLSchema#string

P932

5785105

http://www.w3.org/2001/XMLSchema#string